

## Final Program

## World Hypertension Congress 2009

In conjunction with  
The 11<sup>th</sup> International Symposium on Hypertension and Related Diseases

October 29~November 1, Beijing, China

## Programme

Time	Day 1 – Thursday, October 29, 2009				
Venue	Ballroom 1 (Level 2)	Ballroom 2 (Level 2)	Ballroom 3 (Level 3)	Ballroom 4 (Level 3)	Ballroom 5 (Level 3)
0730-1300	Exhibition Move-In + Registration				
1400-1700		<p><b>SYMPOSIUM 1</b></p> <p><b>DIETARY APPROACH FOR CARDIOVASCULAR HEALTH</b> <i>Chairpersons: Junshi Chen (China); Keyou Ge (China); Zhaosu Wu (China); Arun Chockalingam (Canada); Marcel-Alexandre Juillerat (Switzerland)</i></p> <p>1 Cocoa polyphenols and cardiovascular health - <b>Gary Williamson (UK)</b></p> <p>2 Coffee consumption and cardiovascular morbidity and mortality - <b>Frank B. Hu (US)</b></p>		<p><b>SYMPOSIUM 2</b></p> <p><b>FROM BENCH TO BEDSIDE AND COMMUNITY: WORKING TOGETHER TO MAKE IT IMPLEMENTABLE</b></p> <p>1 (1400-1405) Opening- <b>Lisheng Liu (China)</b></p> <p>Part I: Status Quo <i>Chairpersons: Trefor Morgan (Australia)</i></p> <p>2 (1405-1420) Blood pressure and cardiovascular risk assessment and management: a worldwide perspective <b>Gianfranco Parati (Italy)</b></p> <p>3 (1420-1435) Stroke and hypertension prevention in community from professional perspectives - Trefor Morgan (Australia)</p> <p>4 (1435-1450) Hypertension management in community in China and new health policy – Chonghua Yao (China)</p>	<p><b>SYMPOSIUM 3</b></p> <p><b>TRAINING WORKSHOP: CLINICAL GENETICS</b> <i>Chairpersons: Xingyu Wang (China), Jurg Ott (US)</i></p> <p>1 (1400-1430) Multi-locus analysis in genome-wide case-control association studies - <b>Jurg Ott (US)</b></p> <p>2 (1430-1500) Regulatory genetic variants in complex disorders - <b>David Saffen (US)</b></p> <p>3 (1500-1530) Application of genetic variants and derived biomarkers in clinical medicine - <b>Hakon Hakonarson (US)</b></p> <p>4 (1530-1550) Clinical study design - <b>Xinhua Zhang (HK, China)</b></p>
		<p>3 Milk-derived peptides on blood pressure control- <b>Weiguo Zhang (China)</b></p> <p>4 Salt, hypertension and cardiovascular disease- Prof. <b>Lisheng Liu (China)</b></p>		<p>Part II: Moving from Bench to Bedside and Community - Making It Implementable <i>Chairpersons: Gianfranco Parati (Italy)</i></p> <p>4. (1450-1530) Empower the practice: Helping the practice to update guidelines for BP measurement, HTN diagnosis and treatment - comprehensive CME program - The Netherlands experiences - <b>Gert van Montfrants (The Netherlands), Willem Verberk (The Netherlands)</b></p> <p>5 (1530-1550) Empower the individuals and community: Putting Prevention First - How a charity works with NHS-UK to conduct the population screening and public education program (PEP) in the community - UK experience - <b>Michael Rich (UK)</b></p> <p>6 (1550-1610) Be part of the great movement - From bench to bedside and community. How can industry &amp; government support population screening, CCME program and PE program? - <b>Gert van Montfrants (The Netherlands), Willem Verberk (The Netherlands), Michael Rich (UK)</b></p>	

				7 (1610-1630) Closing and Panel Discussion Trefor Morgan (Australia); Gianfranco Parati (Ita
1830-2100	Opening Ceremony & Welcoming Dinner			

Day 2 – Friday, October 30, 2009					
	Ballroom 1 (Level 2)	Ballroom 2 (Level 2)	Ballroom 3 (Level 2)	Ballroom 4 (Level 3)	Ballroom 5
0730-0820		<b>MORNING COURSE 1</b> <b>HOME BP MONITORING</b> <i>Chairperson: Gianfranco Parati (Italy), Ming Sun (China)</i> <ol style="list-style-type: none"> <li>(0730-0750) Home BP monitoring: the recent European Society of Hypertension Guidelines - <b>Gianfranco Parati (Italy)</b></li> <li>(0750-0810) Home BP monitoring and blood pressure control: a randomized controlled trial - <b>Jiguang Wang (China)</b></li> </ol>	<b>MORNING COURSE 2 (Chi)</b> 早间课堂 (中文) <b>HYPERTENSION MANAGEMENT IN CHILDREN AND ADOLESCENTS (Chi)</b> 儿童和青少年的高血压管理 (中文) <i>Chairperson: Jie Mi (China), Xinhua Tang (China)</i> <ol style="list-style-type: none"> <li>(0730-0745) Waist-to-height ratio is a useful index to identify high blood pressure in obese children and adolescents - <b>Bo Xi (China)</b> 腰围/身高比是诊断肥胖儿童和青少年高血压的有效指标</li> <li>(0745-0800) Optimal waist circumference references to screening cardiovascular risk factors in Chinese children and adolescents - <b>Guansheng Ma (China)</b> 最佳腰围可用于筛选中国儿童与青少年心血管危险因素</li> <li>(0800-0815) The effects of obesity phenotypes on NAFLD and related cardiometabolic risk factors in children - <b>Linghui Meng (China)</b> 肥胖表型对儿童 NAFLD 及心血管相关危险因素的影响</li> <li>(0815-0830) The common rs9939609 variant of the fat mass- and obesity-associated gene is associated with body mass index and risk of obesity in the Chinese children population - <b>Yue Shen (China)</b> 脂肪量和肥胖相关基因的共同 rs9939609 变体与中国儿童肥胖指数和肥胖风险有关</li> </ol>	<b>MORNING COURSE 3</b> <b>Clinical Treatment of Hypertension</b> <i>Chairperson: Hongyi Jin (China), Xiaofang Zhou (China)</i> <ol style="list-style-type: none"> <li>(0730-0750) Bottlenecks and strategies of hypertension therapy - <b>Tianlun Yang (China)</b></li> <li>(0750-0805) Discussion</li> </ol>	<b>MORNING COURSE 4</b> <b>SECONDARY HYPERTENSION</b> <i>Chairperson: Jianjun Mu (China), Stefan Farský (Slovenia)</i> <ol style="list-style-type: none"> <li>(0730-0750) Renal vascular hypertension - <b>Xiongjing Jiang (China)</b></li> <li>(0750-0810) The screening, diagnosis and treatment of primary aldosteronism - <b>Pingjin Gao (China)</b></li> <li>(0810-0820) Discussion</li> </ol>
0830-1000	<b>SYMPOSIUM 4</b> <b>SALT AND HYPERTENSION</b> <i>Chairpersons: Graham MacGregor (UK), Zhiquan Liu TBC (China)</i> <ol style="list-style-type: none"> <li>(0830-0853) Sodium reduction and potassium supplementation reduces blood pressure and improves outcomes from cardiovascular events - <b>Trefor Morgan (Australia)</b></li> <li>(0853-0911) Reducing Dietary Sodium: The Case For Caution! - <b>Michael H. Alderman (USA)</b></li> <li>(0911-0921) The risk factors for high blood pressure among Egyptians, with special emphasis on salt - <b>Hussien Rizk (Egypt)</b></li> <li>(0921-0931) Dietary salt, potassium supplementaton and blood pressure - <b>Jianjun Mu (China)</b></li> <li>(0931-0949) Salt: from evidence to worldwide implementation - <b>Graham MacGregor (UK)</b></li> </ol>	<b>SYMPOSIUM 5</b> <b>BLOOD PRESSURE MEASUREMENT</b> <i>Chairpersons: Jiguang Wang (China), Jan Staessen (Belgium)</i> <ol style="list-style-type: none"> <li>(0815-0835) Ambulatory blood pressure monitoring - <b>Yan Li (China)</b></li> <li>(0835-0855) Automated office blood pressure measurement and the disappearance of the mercury sphygmomanometer - <b>Martin Myers (Canada)</b></li> <li>(0855-0915) Blood pressure monitoring - <b>Yutaka Imai (Japan)</b></li> <li>(0915-0935) Assessment of blood pressure measurement accuracy by electronic duo-control devices in atrial fibrillation patients - <b>Stefan Farský (Slovak League Against Hypertension)</b></li> <li>(0935-0955) ABPM in pregnancy: predictive and</li> </ol>	<b>SYMPOSIUM 6</b> <b>TCM AND HYPERTENSION (Chi)</b> 传统医学与高血压 (中文) <i>Chairpersons: Lanjun Sun (China) Jinxiang Xie (China)</i> <ol style="list-style-type: none"> <li>(0830-0855) The use and strategies of TCM in anti-hypertension - <b>Lanjun Sun (China)</b> 中医抗高血压的策略及其应用</li> <li>(0855-0915) TCM and protection of target organ in hypertension- <b>Zonggui Wu (China) TBC</b> 中医与高血压靶器官保护</li> <li>(0915-0930) The effects of Ruan Mai Ling on the remodeling of cardiac fibrosis in SHR - <b>Liangdi Xie (China)</b> 软脉灵对自发性高血压大鼠心肌纤维化重塑的影响</li> <li>(0930-0945) <i>Radix Astragali</i> postpones organ damage in rat model of metabolic syndrome through the rennin-angiotensin system - <b>Lingling Zhen (China)</b> 黄芪通过肾素血管紧张素系统延缓代谢综合症大鼠模</li> </ol>	<b>SYMPOSIUM 7</b> <b>HYPERTENSION MANAGEMENT IN THE COMMUNITY</b> <i>Chairpersons: Lawrence J. Beilin (Australia), Dongfeng Gu (China)</i> <ol style="list-style-type: none"> <li>(0830-0850) Challenge for hypertension control and prevention in developing countries: unmet needs - <b>Daniel Lemogoum (Cameroon)</b></li> <li>(0850-0905) Public health aspects of high blood pressure and hypertension - <b>Anja Kroke (Germany)</b></li> <li>(0905-0920) Community management of hypertension - <b>Alfredo Duenas (Cuba)</b></li> <li>(0920-0940) Discussion</li> </ol>	

	<p>6 (0949~1000) Discussion</p>	<p>diagnostic tools (automated 24-h blood pressure monitoring in pregnancy) - <b>Stefano Giannubilo (Italy)</b></p> <p>6 (0955-1005) Diagnostic thresholds for ambulatory blood pressure monitoring based on cardiovascular risk: the Finn-Home Study - <b>Teemu Niiranen (Finland)</b></p> <p>7 (1005-1015) Diurnal variation of the augmentation index in young healthy volunteers - <b>Dénes Páll (Hungary)</b></p> <p>8 (1015-1025) Ambulatory Blood Pressure registry for the evaluation of the prognostic threshold in hypertension patients in Korea (Kor-ABP registry) - <b>Jinho Shin (Korea)</b></p>	<p>型器官损伤的研究 5 (0945-1000) Discussion 讨论</p>		
<b>1000-1030 TEA BREAK</b>					
<p>1000-1030 1030-1200</p>	<p><b>SYMPOSIUM 8</b> <b>ISH-WHL JOINT SYMPOSIUM</b> <i>Chairpersons: Anthony Heagerty (UK), Arun Chockalingam (Canada)</i></p> <p>1 (1030-1050) Development of new guidelines and new therapeutics (from a design perspective with a focus on low -resource settings) <b>Lars Lindholm (Sweden)</b></p> <p>2 (1050-1110) Hypertension League and translational medicine' - <b>Lisheng Liu (China)</b></p> <p>3 (1110-1130) Hypertension prevention using a non-modifiable risk factor: genetic markers - <b>Stephen Harrap (Australia)</b></p> <p>4 (1130-1150) Closing the hypertension gap: from what we know to what we do – <b>Arun Chockalingam (Canada)</b></p> <p>5 (1150-1200) Discussion</p>	<p><b>SYMPOSIUM 9</b> <b>ATRIAL FIBRILLATION AND HEART FAILURE</b> <i>Chairpersons : Hans Ibsen (Denmark), Jun Huang (China)</i></p> <p>1 (1030-1050) Antihypertensive treatment and prevention of new onset atrial fibrillation - <b>Hans Ibsen (Denmark)</b></p> <p>2 (1050-1110) Cardiovascular receptors and heart failure - <b>Lin Zhang (China)</b></p> <p>3 (1110-1125) Genetic polymorphisms and atrial fibrillation - <b>Jie-lin Pu (China)</b></p> <p>4 (1125-1150) Debate: RAS blockade in the prevention and treatment of atrial fibrillation <b>Pro: Jun Zhu (China)</b> <b>Con: Jiguang Wang (China)</b></p> <p>6. (1150-1200) Effects of metabolic syndrome on atrial fibrillation in essential hypertensive patients without left ventricular hypertrophy - <b>Liming Lin (China)</b></p>	<p><b>SYMPOSIUM 10</b> <b>ETHNIC AND REGIONAL DIFFERENCES (Chi)</b> 种族与地域差异 (中文)</p> <p><i>Chairpersons: Zengwu Wang, Fanghong Lu (China)</i></p> <p>1 (1030-1050) Gender differences in blood pressure levels in Mongolian Chinese adults <b>Hurile Temuer (China)</b> 中国蒙古族成人血压水平的性别差异</p> <p>2 (1050-1105) Ethnic and gender differences in blood pressure levels in Hui and Han Chinese adults - <b>Jihong Hu (China)</b> 中国回族与汉族成人血压水平的民族与性别差异</p> <p>3 (1105-1120) Ethnic differences in blood pressure levels in Tibetan and Han Chinese adults – <b>Pingcuozhaxi (China)</b></p> <p>4 中国藏族与汉族成人血压水平的差异 <b>(1120-1130) Ethnic and gender differences in blood pressure levels in Uyghur and Han Chinese children and adolescents - Weili Yan (China)</b> 中国维吾尔族与汉族儿童和青少年血压水平的民族与性别差异</p> <p>5 (1130-1140) Prevalence of clustering for current smoking, current drinking and components of metabolic syndrome among adults residents of Lanxi county, Heilongjiang Province, China: results from a cross-sectional study for a poor county - <b>Jingbo Zhao (China)</b> 中国黑龙江省兰溪县成人居民当前吸烟、饮酒及代谢综合征组分集群的现况：来自对贫困县跨区域研究结果</p> <p>6 (1140-1150) Hypertension control in communities: protocol and description of baseline characteristics - <b>Zengwu Wang (China)</b> 社区高血压控制：基线特征描述与方案设计</p> <p>7 (1150-1200) Discussion 讨论</p>	<p><b>SYMPOSIUM 11</b> <b>ENDOTHELIUM</b> <i>Chairpersons: Jeong Bae Park (Korea), Weizhong Zhang (China)</i></p> <p>1 (1030-1050) Endothelial function, vascular biology and hypertension - <b>Rhian M. Touyz (Canada)</b></p> <p>2 (1050-1110) Endothelial progenitor cells, endothelial microparticles and vascular risk - <b>Jun Tao (China)</b></p> <p>3 (1110-1130) RAAS and endothelial dysfunction in patients with hypertension - <b>Suzanne Oparil (USA)</b></p> <p>4 (1130-1145) Functional and structural alterations in hypertensive artery - <b>Jeong Bae Park (Korea)</b></p> <p>5 (1145-1200) Loss of endothelial plasticity as a mechanism for the salt sensitive patient with essential hypertension - <b>Rob Mac Ginley (Australia)</b></p>	<p><b>ABSTRACT PRESENTATIONS 1:</b> <b>TARGET ORGAN DAMAGE</b> <i>Chairpersons: Pingjin Gao (China), Soon-Pyo Hon (Korea)</i></p> <p>1 (1030-1040) Intradialytic hypertension in maintenance hemodialysis patients - <b>Dilip Kirpalani (India)</b></p> <p>2 (1040-1050) Effects of a combination therapy of exercise training and superoxide dismutase mimetic on blood pressure and nitric oxide synthase in spontaneously hypertensive rats - <b>Pengyu Cao (Japan)</b></p> <p>3 (1050-1100) The influence of stroke unit care to mortality and morbidity outcomes in patients surviving first ischemic stroke - <b>Otto Mayer (Czech Republic)</b></p> <p>4 (1100-1110) Prevalence and risk factors of asymptomatic intracranial vascular stenosis in patients with essential hypertension – <b>Min Chen (China)</b></p> <p>5 (1110-1120) Increased arterial stiffness associated with asymptomatic intracranial arterial stenosis and calcification in hypertensive patients - <b>Jin Zhang (China)</b></p>
<p>1200-1330</p>	<p><b>LUNCH SYMPOSIUM</b></p>	<p><b>LUNCH SYMPOSIUM</b></p>	<p><b>LUNCH SYMPOSIUM</b></p>		
<p>1330-1500</p>	<p><b>SYMPOSIUM 12</b> <b>PREHYPERTENSION: CLINICAL MEANING AND MANAGEMENT</b> <i>Chairpersons: A. Chockalingam (Canada), A.</i></p>	<p><b>SYMPOSIUM 13</b> <b>HYPERTENSION AND DIABETES</b> <i>Chairpersons: Zhengpei Zeng (China), Yong Huo (China)</i></p>	<p><b>SYMPOSIUM 14</b> <b>RESISTANT HYPERTENSION (CASE DISCUSSION) (Chi)</b> 顽固性高血压 (病例讨论) (中文)</p>	<p><b>SYMPOSIUM 15</b> <b>CHINA-KOREA JOINT SESSION</b> <i>Chairpersons : Myoung-Mook Lee (Korea), Zhaosu Wu (China)</i></p>	<p><b>ABSTRACT PRESENTATIONS 2:</b> <b>CARDIAC FUNCTION</b> <i>Jun Zhu (China), John E. Sanderson (UK)</i></p>

	<p><b>Zanchetti (Italy)</b></p> <p>1 (1330-1405) <b>Debate: Prehypertension versus high normal blood pressure</b> Prehypertension - <b>Suzanne Oparil (USA)</b> High Normal Blood Pressure - <b>Robert Fagard (Belgium)</b></p> <p>2 (1405-1445) <b>Debate: Drug versus non-drug treatment of prehypertension</b> Drug: <b>Stevo Julius (USA)</b> Non-drug: <b>Alberto Zanchetti (Italy)</b></p> <p>3 (1445-1510) Sympathetic over-activity and excessive cardiovascular risk in prehypertension - <b>Guido Grassi (Italy)</b></p>	<p>1 (1330-1355) Hypertension and diabetes - <b>Michael Hecht Olsen (Denmark)</b></p> <p>2 (1355-1415) Blood pressure management in type 2 diabetes - <b>Naftali Stern (Israel)</b></p> <p>3 (1415-1435) Management of diabetic nephropathy - <b>Qing Xin (China)</b></p> <p>4 (1435-1450) Diabetes and the importance of sodium restriction and other processes to reduce renal damage - <b>Richard James MacIsaac (Australia)</b></p> <p>5 (1450-1500) Discussion</p>	<p><b>Chairpersons : Shaoli Chu, Nanfang Li</b></p> <p>1 (1330-1400) Cause and diagnosis of refractory hypertension: two cases - <b>Hao Wang(China)</b> 顽固性高血压病因诊断</p> <p>2 (1400-1425) Blood pressure-lowering treatment on refractory hypertension - <b>Shaoli Chu (China)</b> 顽固性高血压的降压治疗</p> <p>3 (1425-1450) Treatment for elderly hypertension - <b>Meilin Liu (China)</b> 老年高血压的治疗</p> <p>4 (1450-1500) Higher levels of plasma TNF-<math>\alpha</math> and neuropeptide Y in hypertensive patients with obstructive sleep apnea syndrome - <b>Xiaoguang Yao (China)</b> 伴阻塞性睡眠呼吸暂停综合症高血压患者血浆 TNF -<math>\alpha</math> 与神经肽 Y 水平升高的研究</p>	<p><b>Keynote lectures:</b></p> <p>1 (1330-1350) Hypertension and salt - Intervention to reduce salt intake in Korea - <b>Moo-Yong Rhee (Korea)</b></p> <p>2 (1350-1405) Moderate alcohol drinking and cardiovascular health - <b>Pinming Liu (China)</b></p> <p>3 (1405-1420) Discussion</p> <p><b>Abstract presentation:</b></p> <p>4 (1420-1430) Non-dipper is a determinant of inappropriately high LV mass in essential hypertensive patients - <b>Jinho Shin (Korea)</b></p> <p>5 (1430-1440) Action of salt and health: an evidence-based advocacy approach to make salt reduction a national priority in China - <b>Nicole Li (China)</b></p> <p>6 (1440-1450) Morning HT in treated hypertensives - the baseline characteristics and clinical implications - <b>Dong-Woon Kim (Korea)</b></p> <p>7 (1450-1500) Prehypertension and the risk of heart failure in Chinese older adults - <b>Xuejuan Jin (China)</b></p>	<p>1 (1330-1340) The predictive effects of serum non-high-density lipoprotein cholesterol on the incidence of cardiovascular disease: results from CMCS followed-up 12 years - <b>Jie Ren (China)</b></p> <p>2 (1340-1350) Telomere length predicts left ventricular mass in a general population - <b>Jan A. Staessen (Belgium)</b></p> <p>3 (1350-1400) Changes of collagen metabolism predict the left ventricular remodeling after antihypertensive treatment in hypertensive left ventricular hypertrophy rats - <b>Min Lu (China)</b></p> <p>4 (1400-1410) Independent relations of left ventricular structure with the 24-h urinary excretion of sodium and aldosterone - <b>Yu Jin (Belgium)</b></p> <p>5 (1410-1420) Prognostic value of N-terminal pro-brain natriuretic peptide in patients with heart failure and preserved left ventricular ejection fraction - <b>Chen Hui (China)</b></p> <p>6 (1420-1430) The effect of verapamil and nitroglycerin on the coronary slow flow phenomenon - <b>Shufu Chang (China)</b></p> <p>7 (1430-1440) Effects of 3'-phosphoinositide-dependent protein kinase-1 on the hypoxic neonatal rat cardiomyocytes and myocardium in the rat myocardial infarction - <b>Tae-Jin Shim (South Korea)</b></p> <p>8 (1440-1450) Improving cardiovascular risk stratification in essential hypertensives by indexing left ventricular mass to height<sup>2.7</sup> - <b>Meilikemu Maisaidi (China)</b></p>
--	--	---	--	--	--

**1500-1530 TEA BREAK**

<p><b>1500-1530</b></p> <p><b>1530-1700</b></p>	<p><b>Chairpersons: Liu Lisheng (China), Suzanne Oparil (USA)</b></p> <p>5 (1530-1555) Prehypertension in different ethnic groups - <b>Yuqing Zhang (China)</b></p> <p>6 (1555-1620) Prehypertension, obesity and diabetes - <b>Peter Nilsson (Sweden)</b></p> <p>7 (1620-1645) Organ damage in prehypertension - <b>Hans Ibsen (Denmark)</b></p> <p>8 (1645 - 1700) Discussion</p>	<p><b>SYMPOSIUM 16</b></p> <p><b>HYPERTENSION AND THE AUTONOMIC NERVOUS SYSTEM</b> (Dedicated to the memory of Jacques de Champlain) <b>Chairpersons: Guido Grassi (Italy), Meilin Liu (China)</b></p> <p>1 (1530-1550) Keynote: Sympathetic function in CV disease - <b>Guido Grassi (Italy)</b></p> <p>2 (1550-1610) Role of sympathetic overactivity in the metabolic syndrome - <b>Stevo Julius (USA)</b></p> <p>3 (1610-1630) The role of the central nervous system and autonomic nervous system in hypertension - <b>Simon Rabkin (Canada)</b></p> <p>4 (1630-1650) Evoked catecholamine release from sympathetic nerve terminals in cardiac slices - <b>Zhuan Zhou (China)</b></p>	<p><b>SYMPOSIUM 17</b></p> <p><b>SPECIAL TYPES OF HYPERTENSION (Chi)</b> 特殊类型高血压 (中文) <b>Chairpersons: Chengzong Zhang (China), Pingjin Gao (China)</b></p> <p>1 (1530-1550) Transplantation and Hypertension - <b>Qiuyan Dai (China)</b> 移植与高血压</p> <p>2. (1550-1610) Atherogenic index and hypertensive renal injury 动脉硬化指数与高血压肾功能损伤 - <b>Pingjin Gao (China)</b></p> <p>3. (1610-1630) Association of homocysteine with hypertension and cardiovascular disease - <b>Haiying Wu (China)</b></p>	<p><b>SYMPOSIUM 18</b></p> <p><b>RESISTANT HYPERTENSION</b> <b>Chairpersons: Zhiming Zhu (China), Michael O'Rourke (Australia)</b></p> <p>1 (1530-1550) Resistant hypertension - can we do more? - <b>Lars Hjalmar Lindholm (Sweden)</b></p> <p>2 (1550-1610) Recent advances in hypertension; focus on aortic pressure - <b>Michael O'Rourke (Australia)</b></p> <p>3 (1610-1630) Endocrine hypertension - <b>Zhengpei Zeng (China)</b></p> <p>4 (1630-1650) Resistant hypertension - pay attention to secondary hypertension - <b>Nanfang Li(China)</b></p>	<p><b>SYMPOSIUM 19</b></p> <p><b>BLOOD VESSELS</b> <b>Chairpersons : Xinli Li (China) Anthony Heagerty (UK)</b></p> <p>1 (1530-1550) <i>Keynote Lecture:</i> Inflammation and vascular remodeling - <b>Ernesto Schiffrin (Canada)</b></p> <p>2 (1550-1610) Perivascular fat and its effect on blood vessel tone and its role in the pathology of metabolic syndrome - <b>Anthony Heagerty (UK)</b></p> <p>3 (1610-1630) Small arteries (prognostic significance and effect of treatment) - <b>Enrico Agabiti Rosei (Italy)</b></p> <p>4 (1630-1650) Measurement of arterial</p>
---	---	--	--	---	---

**World Hypertension Congress 2009 (Oct 29~Nov 1, 2009)**

		5 (1650-1700) Discussion	同性半胱氨酸与高血压及心血管疾病 4. (1630-1650) Discussion	6 (1650-1700) Hypertensive crises - Abdulhamid Kashgari (Saudi Arabia)	stiffness in daily practice - <b>Luc Van Bortel (Belgium)</b> 5 (1650-1705) Microcirculation and hypertension? - <b>Xiuhua Liu (China)</b> 6 (1705-1715) Noninvasive arterial stiffness indices and cardiovascular risk in hypertensive patients - <b>Junli Zuo (China)</b>
1700-1800			<b>EVENING SYMPOSIUM</b>		

## Day 3 – Saturday, 31 October, 2009

	Ballroom 1 (Level 2)	Ballroom 2 (Level 2)	Ballroom 3 (Level 2)	Ballroom 4 (Level 3)	Ballroom 5
0730-0820		<b>MORNING COURSE 5</b>  <b>J-CURVE</b> <i>Chairperson: Ningling Sun (China), Peter Meredith (UK)</i>  1 (0730-0750) The blood pressure J-curve: fact or fiction? - <b>Peter Meredith (UK)</b>  2 (0750-0810) Risk of low blood pressure in the elderly - <b>Tomasz Grodzicki (Poland)</b>  3 <b>(0810-0820) Discussion</b>	<b>MORNING COURSE 6</b>  <b>BLOOD PRESSURE MEASUREMENT (Chi)</b> 血压测量 (中文) <i>Chairperson: Jiguang Wang (China), Jinxiang Xie (China)</i>  1. <b>(0730-0745)</b> Ambulatory blood pressure – <b>Weizhong Zhang (China)</b> 动态血压  2. (0745-0800) The role of non-clinical setting blood pressure measurement in the diagnosis and treatment of hypertension - Jinxiang Xie (China)  非诊室血压测量在高血压诊治中的作用  (0800–0810) Discussion讨论	<b>MORNING COURSE 7</b>  <b>TRANSLATIONAL MEDICINE</b> <i>Chairperson: Kikuo Arakawa (Japan); Hongliang Cong (China)</i>  1 <b>(0730-0750)</b> Blood pressure management: translating evidence into practice in Australia - <b>Nancy Huang (Australia)</b>  2 <b>(0750-0810)</b> Bulgarian consensus on monotherapy and combination therapy of arterial hypertension and focus on fixed combinations – <b>Svetla Torbova (Bulgaria)</b>  3 <b>(0810-0820) Discussion</b>	
0830-1000	<b>SYMPOSIUM 20</b>  <b>WORKSITE HYPERTENSION MANAGEMENT</b> <i>Chairpersons: Arun Chockalingam (Canada), George Fodor (Canada)</i>  1 <b>(0830-0855)</b> Keynote: The worksite: a base for cardiovascular disease management – <b>Michael Alderman (USA)</b>  2 <b>(0855-0915)</b> Lessons learnt from worksite-based hypertension detection programs in central Europe - <b>George Fodor (Canada)</b>  3 <b>(0915-0935)</b> Real-life medicine and therapy of hypertension – lessons from worksite studies and population trials from Slovakia - <b>Jan Lietava, Bratislava (Slovak)</b>  4 <b>(0935-0955)</b> It should be community-based and long-term intervention program to control the burden of hypertension and related diseases in China - an example in Shougang - <b>Xinhua Zhang (China)</b>  5 <b>(0955-1000) Discussion</b>	<b>SYMPOSIUM 21</b>  <b>CHINA- ITALY JOINT SESSION: BLOOD PRESSURE CONTROL</b> <i>Chairpersons: Guido Grassi (Italy), Zhaosu Wu (China)</i>  1 <b>(0830-0855)</b> Blood pressure control: the situation in Europe - <b>Guido Grassi (Italy)</b>  2 <b>(0855-0915)</b> Blood pressure control in Asia - <b>Jiguang Wang (China)</b>  3 <b>(0915-0935)</b> BP control and guidelines - <b>Alberto Zanchetti (Italy)</b>  4 <b>(0935-0955)</b> New drug development - <b>Thomas Unger (Germany)</b>  5 <b>(0950-1000) Discussion</b>	<b>SYMPOSIUM 22</b>  <b>HYPERTENSION MANAGEMENT IN THE COMMUNITY (Chi)</b> 社区高血压管理  <i>Chairpersons: Wen Wang (China), Manlu Zhu (China)</i>  1 <b>(0830-0855)</b> Strategies for prevention and treatment of cardiovascular diseases in China - <b>Dongfeng Gu (China)</b> 中国心脑血管病防治策略 2 <b>(0855-0915)</b> Optimizing management of hypertension with combination therapy - <b>Wen Wang (China)</b> 基层高血压优化降压治疗 3 <b>(0915-0935)</b> Staged results of standardized community hypertension management in China - <b>Zengwu Wang</b> 全国社区高血压规范化管理阶段结果 4 <b>(0935-0950)</b> Spreading standardized management of hypertension in the community of Jiangsu Province - <b>Quanyong Xiang</b> 江苏省社区高血压规范化管理推广 5 <b>(0950-1000) Discussion</b> 讨论	<b>SYMPOSIUM 23</b>  <b>OBESITY AND METABOLIC SYNDROME</b> <i>Chairpersons: Lawrence Beilin, Chunming Chen (China)</i>  1 <b>(0830-0850)</b> Role of high normal blood pressure in the metabolic syndrome, obesity and diabetes - <b>Marzena Chrostowska (Poland)</b>  2 <b>(0850-0905)</b> Relationship between ethnic background and adiposity - <b>Scott Lear (Canada)</b>  3 <b>(0905-0920)</b> Origins of the metabolic syndrome and cardiovascular disease – <b>Lawrence Beilin (Australia)</b>  4 <b>(0920-0935)</b> Treatment of hypertension in obesity - <b>Oswaldo Kohlmann (Brazil)</b>  5 <b>(0935-0950)</b> Activation of TRPV1 by dietary capsaicin prevents obesity and hypertension - <b>Zhiming Zhu (China)</b>  6 <b>(0950-1000)</b> Relative risk on cardiovascular risk factors of obesity defined by waist and BMI - <b>Songming Du (China)</b>	<b>ABSTRACT PRESENTATIONS 3:</b>  <b>LIPIDS, ATHEROSCLEROSIS</b> <i>Chairpersons: Daowen Wang (China)</i>  1 <b>(0830-0840)</b> Linoleic acid deficiency in human myocardium with dilated cardiomyopathy and coronary artery disease with heart failure - <b>Ning Zhu (China)</b>  2 <b>(0840-0850)</b> The effects of hypertension on plasma HDL subclass concentrations in patients with and without CHD - <b>Yihong Ren (China)</b>  3 <b>(0850-0900)</b> C-reactive protein induced the expression of receptor for advanced glycation end products via NF-κB - <b>Zhong Yun (China)</b>  4 <b>(0900-0920)</b> Heparin inhibits the production of matrix metalloproteinase-2 and improves atherosclerosis in LDL receptor-deficient mice - <b>Fukang Xu (China)</b>  5 <b>(0920-0930)</b> Angiotensin II decreases cholesterol 27-hydroxylase expression and promotes foam cell formation in THP-1 - <b>Gang Tian (China)</b>  6 <b>(0930-0940)</b> WIN55,212-2 via CB2 receptor attenuates TNF-α and ROS in RAW264.7 macrophages by activating ERK1/2 signaling- <b>Mingxiu Hao (China)</b>  7 <b>(0940-0950)</b> Effect of total flavonoids of Hippophae rhamnoides L. on the Expression of Mcp-1 in Aorta of Spontaneously Hypertensive Rats- <b>Jun He (China)</b>

1000-1030		TEA BREAK		1000-1030	
1030-1200	<b>SYMPOSIUM 24</b> <b>LATE BREAKING STUDIES (1)</b> <i>Chairpersons: Dayi Hu (China), Lars Hjalmar Lindholm (Sweden)</i> 1 (1030-1050) CHIEF trial - <b>Wen Wang (China)</b> 2 (1050-1100) Benefits of nifedipine GITS in stable coronary artery disease: further analysis of the "ACTION" database - <b>Peter Meredith (UK)</b> 3 (1105-1115) CHINOM study - <b>Yuqing Zhang (China)</b> 4 (1110-1120) Ontarget study: Chinese data – <b>Litian Yu (China)</b> 5 (1120-1130) A multicenter, randomized, proof-of-concept, parallel-controlled study with Remind Cap® in patients with essential hypertension newly treated with valsartan ± hydrochlorothiazide - <b>Lip Ping Low (Singapore)</b> 6 (1130-1140) CHINA STATUS - <b>Chonghua Yao(China)</b> 7 (1140-1150) The effect of replacing regular salt with SmartSalt® mineral salt on blood pressure in middle-aged subjects with high normal blood pressure or with mild hypertension - <b>Essi Sarkkinen (Finland)</b>	(Cont') <i>Chairpersons: Enrico Agabiti Rosei (Italy), Dngliang Zhu (China)</i> 5 (1030-1050) Barriers to blood pressure control - <b>Robert Fagard (Belgium)</b> 6 (1050-1110) How to improve BP control - <b>Athanasios Manolis (Greece)</b> 7 (1110-1130) Blood pressure control and detailed management of hypertension in Shanghai community hospitals - <b>Yi Zhang (China)</b> 8 (1130-1150) Targeting hypertension with a new ATP-Sensitive potassium channel opener iptalalim— <b>Hai Wang (China)</b> 9 (1150-1200) Discussion	(Cont') <i>Chairpersons: Shuping Ma (China), Kegui Wu (China)</i> 6 (1030-1050) Treatment development of hypertension- <b>Jinxiu Lin (China)</b> 高血压治疗新进展 7 (1050-1105) Treatment of hypertension in rural areas of Liaoning Province - <b>Yingxian Sun</b> 辽宁农村高血压治疗 8 (1105-1120) Community hypertension management in Zhejiang Province - <b>Xinhua Tang(China)</b> 浙江高血压社区三化管理 9 (1120-1140) - Control of Morning Blood Pressure Surge - <b>Ningling Sun (China)</b> 晨峰高血压的控制 10 (1140-1200) Management of systolic hypertension in the elderly - <b>Lianyou Zhao(China)</b> 老年收缩期高血压的治疗	<b>SYMPOSIUM 25</b> <b>EPIDEMIOLOGY</b> <i>Chairpersons :Gu Dongfeng, Zhaosu Wu (China)</i> 1 (1030-1045) Prehypertension and risk of incidence and mortality of cardiovascular disease in Chinese adults - <b>Dongfeng Gu (China)</b> 2 (1045-1100) Comparative evaluation of prevalence of hypertensive phenotypes by using home and office blood pressure measurements in treated and untreated subjects over the age of 55 - <b>Elena Platonova (Russia)</b> 3 (1100-1115) Predictors of ischemic cardiovascular disease in middle-age Chinese with optimal low-density lipoprotein cholesterol - <b>Jing Liu (China)</b> 4 (1115-1130) Blood pressure and lipid control rates in hypertensive populations with or without diabetes mellitus - <b>Theoharis Livieratos (Greece)</b> 5 (1130-1145) Control of the cardiovascular risk factors in the Spanish population - <b>Gegorio Mediavilla (Spain)</b> 6 (1145-1200) Resting heart rate and cardiovascular death in the Chinese population sample - <b>Xiaoqing Liu(China)</b> 7 (1200-1210) An overview of public health surveillance of hypertension in Canada - <b>Sulan Dai (Canada)</b>	<b>Workshop 1</b> <b>REDUCING DIETARY SALT: THE WORLD, CHINA AND THE AMERICAS</b> <i>Chairpersons: N. Campbell (Canada)</i> 1. (1000-1030): Overview of the scientific rationale and the role of WASH and WHL- <b>G. MacGregor (UK)</b> 2. (1030-1045) C-WASH: <b>Nicole Li (China)</b> 3. (1045-1000): PAHO policy recommendations 4. (1000-1100) Workshop
1200-1330	LUNCH SYMPOSIUM	LUNCH SYMPOSIUM			
1330-1500	<b>SYMPOSIUM 26</b> <b>RENIN-ANGIOTENSIN SYSTEM</b> <i>Chairpersons: Hans Brunner (Switzerland), Yuhua Dai (China)</i> 1 (1330-1350) Overview of the physiology of the RAAS - <b>Haralambos Gavras (USA)</b> 2 (1350-1410) Function of the (pro)renin receptor - <b>Geneviève Nguyen (France)</b> 3 (1410-1430) What to expect from renin inhibitors beyond ARBs? - <b>Michel Azizi (France)</b> 4 (1430-1450) RAS inhibitor and atrial fibrillation in hypertension: anti-inflammation or anti-hypertension- <b>Guangping Li (China)</b> 5 (1450-1500) Discussion	<b>SYMPOSIUM 27</b> <b>HEART AND HYPERTENSION</b> <i>Chairpersons : Anja Kroke (Germany), Yongxin Lu (China)</i> 1 (1330-1350) HFpHF and hypertension - <b>Yongxin Lu (China)</b> 2 (1350-1405) Hypertensive heart disease, mechanisms and consequences - <b>Thomas Kahan (Sweden)</b> 3 (1405-1420) Hypertension and multiple CVD risk factors in Chinese: results from the CONSIDER study - <b>Dong Zhao (China)</b> 4 (1420-1435) Hypertension-induced coronary artery disease - <b>Simon Rabkin (Canada)</b> 5 (1435-1445) Higher prevalence of left ventricular hypertrophy in octogenarian women: the Jerusalem Longitudinal Cohort Study - <b>Michael Bursztyn (Israel)</b>	<b>SYMPOSIUM 28</b> <b>CHINESE SESSION: HYPERTENSION PRACTICE (Chi)高血压治疗</b> <i>Chairpersons : Tingjie Zhang (China), Yinsheng Wu (China)</i> 1 (1330-1350) Lipid management in hypertension - <b>Yong Li (China)</b> 高血压的血脂管理 2 (1350-1405) Treatment of hypertension in heart Failure - <b>Lin Zhang (China)</b> 高血压心力衰竭的处理 3 (1405-1420) Diabetes management in hypertension - <b>Zhangrong Xu (China)</b> 高血压糖尿病处理 4 (1420-1435) Screening of secondary hypertension - <b>Shaoli Chu (China)</b> 继发性高血压的筛查处理 5 (1435-1450) Management of resistant hypertension – <b>Haiying Wu (China)</b> 难治性高血压的处理 6 (1450-1500) Discussion 讨论	<b>SYMPOSIUM 29</b> <b>CHINA-JAPAN JOINT SESSION</b> <i>Chairpersons : Kazuaki Shimamoto (Japan), Zhaosu Wu (China)</i> <b>Session I: Special Lecture</b> 1 (1330-1350) Cardiovascular risk in relation to the interaction between blood pressure and vessels - <b>Jiguang Wang (China)</b> 2 (1350-1410) Management of elderly hypertension from the aspect of geriatric medicine - <b>Hiroshi Rakugi (Japan)</b> <b>Session 2: Oral Presentation</b> <i>Chairpersons: Weizhong Zhang (China), Yinong Jiang, (China), Masatsugu Horiuchi (Japan), Jitsuo Higaki (Japan)</i> 1 (1410-1420) Calcium antagonist in the prevention of stroke in Asian hypertensive patients - <b>Yuqing Zhang (China)</b> 2 (1420-1430) Angiotensin II type 1 receptor-	<b>SYMPOSIUM 30</b> <b>HIGHCARE PROJECT: HYPOXIA AT ALTITUDE AND CARDIOVASCULAR REGULATION</b> <i>Chairpersons : Xiansheng Cheng (China), Gianfranco Parati (Italy)</i> 1 (1330-1355) Effects of hypoxia on conventional and ambulatory arterial pressure - <b>Gianfranco Parati (Italy)</b> 2 (1355-1415) pulmonary artery pressure – <b>Wanmu Xie (China)</b> 3 (1415-1435) Effects of hypoxia on pulmonary artery pressure - <b>Pietro Amedeo Modesti (Italy)</b> 4 (1435-1450) – Discussion

		<p>6 (1445-1455) Circadian rhythm of heart rate and its association with target organ damage in treated essential hypertensive patients - <b>Pingjin Gao (China)</b></p>		<p>associated protein prevents vascular smooth muscle cell senescence via an inactivation of calcineurin/nuclear factor of activated t cells pathway - <b>Min L.J. (Japan)</b></p> <p>3 (1430-1440) Pattern recognition receptor signals – a new approach to atherosclerosis - <b>Yanchun Ding (China)</b></p> <p>4 (1440-1450) Nanoparticle-mediated delivery of angiotensin II receptor antagonist, olmesartan medoxomil into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension in rats - <b>Chen L. (Japan)</b></p> <p>5 (1450-1500) Prognostic value of isolated nocturnal hypertension in 8,711 subjects from 10 populations - <b>Yan Li (China)</b></p> <p>6 (1500-1510) Stretch-induced activation of rho/rho-kinase pathway as a determinant of malignant phenotype of adipose tissue in diet-induced obesity - <b>Hara Y. (Japan)</b></p> <p>7 (1510-1520) Microalbuminuria associated with TNF-<math>\alpha</math> and large arterial stiffness in Chinese hypertensive patients - <b>Xinli Li (China)</b></p> <p>8 (1520-1530) Lectin-like oxidized LDL receptor-1 and vascular injury by Rac1 activation under chronic hypoxia - <b>Ogura S. (Japan)</b></p> <p>(1530-1540) Discussion</p>	
1500-1530		<b>TEA BREAK</b>			
1530-1700	<p><b>RENIN-ANGIOTENSIN SYSTEM (CONT')</b></p> <p><i>Chairpersons: Thoma Unger (Germany), Dingliang Zhu (China)</i></p> <p>6 (1530-1545) Choosing the right dose for RAS-blockade - <b>Peter A. Meredith (UK)</b></p> <p>7 (1545-1600) Clinical importance of potassium in cardiovascular medicine - <b>George Dolson (USA)</b></p> <p>8 (1600-1615) Mineralocorticoid, potassium and experimental cardiovascular remodeling - <b>Qing Wang (Switzerland)</b></p> <p>9 (1615- 1630) New development of renin inhibitors - <b>Thomas Unger (Germany)</b></p> <p>10 (1630-1645) Potential use of aldosterone synthase inhibitors - <b>Hans Brunner (Switzerland)</b></p> <p>11 (1645-1700) Discussion</p>	<p><b>SYMPOSIUM 31</b></p> <p><b>KIDNEY AND HYPERTENSION</b></p> <p><i>Chairpersons : Hans Ibsen (Denmark), Falei Zheng (China)</i></p> <p>1 (1530-1550) Monitoring of microalbuminuria in hypertension - <b>Hans Ibsen (Denmark)</b></p> <p>2 (1550-1605) Lipids and statins in renal disease and hypertension - <b>Luis Juncos (Brazil)</b></p> <p>3 (1605-1620) Hypertension and kidney transplantation - <b>Bruno Watschinger (Austria)</b></p> <p>4 (1620-1635) Chronic kidney disease and hypertension: the deadly duo - <b>Adel E. Berbari (Lebanon)</b></p> <p>5 (1635-1650) Hypertension and glomerulosclerosis - <b>Guangyan Cai (China)</b></p> <p>6 (1650-1700) The relationship between ambulatory pulse pressure coherent index and early renal injury in elderly patients with primary hypertension - <b>Huijuan Kou (China)</b></p>	<p><b>SYMPOSIUM 32</b></p> <p><b>HYPERTENSION AND HEART FAILURE (Chi)</b></p> <p>高血压与心衰</p> <p><i>Chairpersons : Fusheng Gu (China), Yongxin Lu (China),</i></p> <p>1. (1530-1545) Hypertension and diastolic heart failure - <b>Yongxin Lu (China)</b></p> <p>高血压与舒张性心力衰竭</p> <p>2. (1545-1600) New treatment strategy for left ventricular systolic dysfunction – <b>Jian Zhang (China)</b></p> <p>急性左心功能衰竭的治疗进展</p> <p>3. (1600- 1615) Hypertension and alcohol - <b>Hongwei Li (China)</b></p> <p>4. (1615-1630) Hypertension and acute heart failure - <b>Luhua Shen (China)</b></p> <p>高血压急性心衰</p> <p>5. (16530-1645) Therapeutic hypothermia---- Application in Heart Arrest and Acute Myocardial Infarction - <b>Tao Zhenyin (USA)</b></p>	<p><b>Session 3: Poster Presentation</b></p> <p>(1550-1700)</p> <p><i>Chairpersons from China: Xiaowei Yan, Nanfang Li, Zhiming Zhu, Xinli Li</i></p> <p><i>Chairpersons from Japan: Kensuke Egashira, Tatsuo Shimomura, Masaru Iwai, Hisashi Adachi</i></p> <p>20 posters for each side, divided into four groups for poster discussion</p>	<p><b>ABSTRACT PRESENTATIONS 4:</b></p> <p><b>OBESITY, METABOLIC SYNDROME, DIABETES</b></p> <p>1 <b>Yong Li (China), Lip Ping Low (Singapore)</b></p> <p>1 (1530-1540) Optimal waist circumference for Chinese adults for predicting hypertension and metabolic syndrome - <b>Guansheng Ma (China)</b></p> <p>2 (1540-1550) Relationship of inflammatory factors and von Willebrand factor with metabolic syndrome in Chinese hypertensive subjects - <b>Jing Liu (China)</b></p> <p>3 (1550-1600) The comparison of lipids and high sensitivity C-reactive protein in different state of insulin resistance in obese hypertensive patients - <b>Fuqiang Liu (China)</b></p> <p>4 (1600-1610) Perivascular fat-mediated vascular dysfunction and remodeling via AMPK/mTOR pathway in high fat diet-induced</p>

**World Hypertension Congress 2009 (Oct 29~Nov 1, 2009)**

			心脏骤停与心肌梗死中的低氧问题处理 <b>6. (1645-1700) Discussion 讨论</b>		obese rats - <b>Zhidan Luo (China)</b> 5 <b>(1610-1620) Relationship between C-reactive protein and visceral fat obesity and their impacts on target organ damage - Zhidan Luo (China)</b>
<b>1700-1800</b>			<b><i>EVENING SYMPOSIUM</i></b>		

Day 4 – Sunday, November 1, 2009					
	Ballroom 1 (Level 2)	Ballroom 2 (Level 2)	Ballroom 3 (Level 3)	Ballroom 4 (Level 3)	Ballroom 5
			<p><b>MORNING COURSE 8:</b> 早间课堂</p> <p><b>EMERGING PROBLEMS OF HYPERTENSION MANAGEMENT (CHI)</b> 高血压防治中的新问题(中文)</p> <p><i>Chairpersons: Tingjie Zhang (China), Yinsheng Wu (China)</i></p> <p>1. (0730-0750) Hypertension and dementia- <i>Jinquan Wang (China)</i> 高血压与痴呆</p> <p>2. (0750-0810) Pharmacogenomics of "H" type hypertension: from treatment to prevention - <i>Xiping Xu (China)</i> H-型高血压的药物基因组学: 从治疗到预防</p> <p>3. Discussion 讨论</p>	<p><b>MORNING COURSE 9:</b></p> <p><b>PHARMACOGENOMICS AND PHARMACOGENETICS</b></p> <p><i>Chairpersons: Xingyu Wang (China), Xinhua Zhang (China)</i></p> <p>1 (0730-0750) Predicting warfarin dose with pharmacogenetic algorithms - <i>Ming Ta, Michael Lee (Taiwan, China)</i></p> <p>2 (0750-0805) ACE isoforms as a biologic marker of hypertension - <i>Frida L. Plavnik (Brazil)</i></p> <p>3 (0805-0820) The impact of the SLC1B1 gene polymorphism on the lipid-lowering effect of pitavastatin - <i>Meizhen Zhang (China)</i></p>	<p><b>MORNING COURSE 10:</b></p> <p><b>BLOOD PRESSURE MANAGEMENT IN CHRONIC RENAL INSUFFICIENCY</b></p> <p><i>Chairpersons: Guangyan Cai (China); Marius Miglinas (Lithuania)</i></p> <p>1. (0730-0755) Hypertension and kidney - <i>Marius Miglinas (Lithuania)</i></p> <p>2. (0755-0815) Control of hypertension in chronic renal failure patients - <i>Adarsh Babu (UK)</i></p>
0830-1000	<p><b>SYMPOSIUM 33</b></p> <p><b>CLINICAL TRIALS: HOW TO TRANSLATE INTO PRACTICE</b> <i>Chairpersons: Jan Staessen (Belgium), Ming Sun (China)</i></p> <p>1 (0830-0850) Blood pressure lowering in normotensive or controlled hypertensive patients without heart failure - <i>Jiguang Wang (China)</i></p> <p>2 (0850-0910) Blood pressure lowering for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature - <i>Zengwu Wang (China)</i></p> <p>3 (0910-0930) Keynote: Update of recent clinical trials: do results support conclusions? - <i>Jan Staessen (Belgium)</i></p> <p>4 (0930-0950) Frail elderly patients with hypertension - <i>Tomasz Grodzicki (Poland)</i></p> <p>5 (0950-1000) Morbidity and mortality on combination versus monotherapy in the Systolic Hypertension in Europe trial - <i>Jan Staessen (Belgium)</i></p>		<p><b>SYMPOSIUM 34</b></p> <p><b>CHINA- INDIA JOINT SESSION: PRIMARY HEALTHCARE RESPONSE TO HYPERTENSION AND DIABETES</b> <i>Chairpersons: K. Srinath Reddy (India), Zhaosu Wu (China)</i></p> <p>1 (0830-0850) Applied research of disease management preprogrammed for hypertension in the community - <i>Xinhua Tang (China)</i></p> <p>2 (0850-0910) A Health System Approach to Hypertension and Diabetes - <i>K. Srinath Reddy (India)</i></p> <p>3 (0910-0925) Current strategies and practice on primary care-based hypertension and diabetes control in China - <i>Xinhua Zhang (China)</i></p> <p>4 (0925-0940) Preparing the Health Workforce for Chronic Disease Management in Primary Health Care - <i>Sailesh Mohan (India)</i></p> <p>5 (0950-1000) Discussion</p>	<p><b>ABSTRACT PRESENTATION 5:</b></p> <p><b>CLINICAL ASPECTS</b></p> <p>1 <i>Chairpersons: Osvaldo Kohlmann (Brazil); Lin Zhang (China)</i></p> <p>1 (0830-0840) Dietary intervention: why is there still so little support for sodium restriction? A personal viewpoint - <i>John B. Myers (Australia)</i></p> <p>2 (0840-0850) T-type Ca<sup>2+</sup> channel antagonists and hypertension - <i>Zhengang Wang (China)</i></p> <p>3 (0850-0900) Comparison of ACE inhibitors and ARBs on incidence of major adverse cardiac events in patients with cardiovascular disease: a meta-analysis - <i>Panpan Hao (China)</i></p> <p>4 (0900-0910) Evaluating factors associated with compliance to thiazide diuretics among 8,551 Chinese patients - <i>Martin Wong, Chi Sang (HK, China)</i></p> <p>5 (0910-0920) Electrocardiographic and echocardiographic parameters in hypertensive patients with chest pain concomitant with CAD (coronary artery disease) or with normal or minimal CAD - <i>Young-bok Kim (South Korea)</i></p> <p>6 (0920-0930) Plasma cathepsin I and its extracellular matrix cleavage product, endostatin, play useful roles in predicting poor coronary collateral in patients with coronary artery disease - <i>Jin Zhang (China)</i></p> <p>7 (0930-0940) Cytomegalovirus infection and innate immune response in preeclampsia:</p>	<p><b>ABSTRACT PRESENTATIONS 6:</b></p> <p><b>EXPERIMENTAL HYPERTENSION</b></p> <p><i>Chairpersons: Xiong-Jing Jiang (China); Xiaohu Chen (China)</i></p> <p>1 (0830-0840) Complement C3 is involved in adventitial fibroblast phenotypic differentiation induced by angiotensin-II and TGF-beta 1 - <i>Shujie Guo (China)</i></p> <p>2 (0840-0850) High salt diet alters NF-κB and CREB DNA binding activities in the heart, kidney and hypothalamus of spontaneously hypertensive rats - <i>Qianhui Shang (China)</i></p> <p>3 (0850-0900) Inhibitory effect of D3 dopamine receptors on insulin receptor expression and function in vascular smooth muscle cells - <i>Hefei Huang (China)</i></p> <p>4 (0900-0910) Interleukin-6 promoter -174G/C polymorphism and hypertension: a case-control study and a meta-analysis - <i>Wenquan Niu (China)</i></p> <p>5 (0910-0920) The effect of orally single dose of slow-release isosorbide-5-mononitrate on central blood pressure in healthy volunteers - <i>Xiong-Jing Jiang (China)</i></p> <p>6 (0920-0930) Activation of TRPV1 inhibits angiotensin II induced</p>

				<p>a link between preeclampsia and later cardiovascular disease?- <b>Cindy Fang (Canada)</b></p> <p>8 <b>(0940-0950)</b> The relationship between visfatin and HOMA-IR in hypertensive patients - <b>Jianjun Lan (China)</b></p>	<p>vasoconstriction in mice - <b>Zhidan Luo (China)</b></p> <p>7 <b>(0930-0940)</b> Effects of atrial natriuretic peptide on ion pump activity and gene expression in aortic smooth muscle cells from spontaneously hypertensive rats - <b>Qianhui Shang (China)</b></p> <p>8 <b>(0940-1000)</b> ACEI can improve apoptosis myocardium of patients with primary hypertension - <b>Gao Chuanyu (China)</b></p> <p>9 <b>(1000-1010)</b> Intervention study of rat cardiomyocytes <math>\beta</math>1-adrenergic receptor gene methylation modification - <b>Du Xia (China)</b></p> <p>10 <b>(1010-1020)</b> Increased migration of monocytes associated with enhanced transient receptor potential canonical Type 3 channels in human essential hypertension - <b>Zhidan Luo (China)</b></p>
<b>1000-1030</b>	<b>TEA BREAK</b>				
<b>1030-1200</b>	<p><b>SYMPOSIUM 35</b></p> <p><b>TRANSLATIONAL MEDICINE</b> <i>Chairpersons: Peter Sleight (UK), Xiping Xu (China)</i></p> <p>2 <b>(1030-1055)</b> Keynote: Translational medicine - a look at what is meant by this fashionable concept - <b>Peter Sleight (UK)</b></p> <p>3 <b>(1055-1110)</b> PROCOR - <b>Vikas Saini (Canada)</b></p> <p>4 <b>(1110-1125)</b> Towards integrated strategies to chronic disease prevention: a Canadian perspective - <b>Sylvie Stachenko (Canada)</b></p> <p>5 <b>(1125-1140)</b> Hypertension: awareness to action - <b>Lip Ping Low (Singapore)</b></p> <p>6 <b>(1140-1150)</b> Pre-hypertension and the risk of heart failure - <b>Xuejuan Jin (China)</b></p> <p>7 <b>(1150-1200)</b> Are we doing sufficiently to follow guidelines? - <b>Vilnis Dzerve (Latvia)</b></p>		<p><b>SYMPOSIUM 36</b></p> <p><b>CHINESE HYPERTENSION GUIDELINE (Chi)</b> 中国高血压指南(中文) <i>Chairpersons: Wen Wang (China) and Pingjin Gao (China)</i></p> <p>1 <b>(1030-1045)</b> Evidence-based medicine in China hypertension studies - <b>Yuqing Zhang (China)</b> 中国高血压的临床研究证据</p> <p>2. <b>(1045-1100)</b> Minimum standards in blood lowering treatment - <b>Meilin Liu (China)</b> 降压治疗血压低限值问题</p> <p>2 <b>(1100-1115)</b> Evaluation of <math>\beta</math> blocker treatment to hypertension – <b>Zengwu Wang (China)</b> <math>\beta</math> 受体阻滞剂治疗高血压的评估</p> <p>3 <b>(1115-1135)</b> 2009 Chinese hypertension guidelines – <b>Wen Wang (China)</b> 基层版中国高血压指南</p> <p>4 <b>(1135-1200)</b> Discussion 讨论</p>	<p><b>SYMPOSIUM 37</b></p> <p><b>LATE BREAKING STUDIES (2)</b> <i>Chairpersons: Masatsugu Horiuchi (Japan), Zhang Hongye (China)</i></p> <p>1 <b>(1030-1045)</b> SALT PILOT - <b>Hongye Zhang (China)</b></p> <p>2 <b>(1045-1100)</b> A cohort study of profiles of beta-blocker discontinuation in 19,177 Chinese patients - <b>Martin Wong, Chi Sang (HK, China)</b></p> <p>3</p> <p>4 <b>(1100-1115)</b> Prognostic value of the morning blood pressure surge in 5,645 subjects from 8 populations – <b>Yan Li (China)</b></p> <p>5 <b>(1115-1130)</b> Sex differences in the relationship between waist-hip ratio and silent brain infarction in a multiethnic cohort from the Northern Manhattan Study (NOMAS) - <b>Chuanhui Dong (China)</b></p> <p>6 <b>(1130-1145)</b> FEVER - <b>Yuqing Zhang (China)</b></p> <p>7 <b>(1145-1200)</b> Implementation of an innovative community-based hypertension disease management program in Hangzhou, China - <b>Xinhua Tang (China)</b></p>	<p><b>ABSTRACT PRESENTATIONS 7:</b></p> <p><b>BASIC SCIENCES</b> <i>Chairpersons: Cheol-Ho Kim (Korea), Tzung-Dau Wang (Taiwan, China)</i></p> <p>1 <b>(1030-1040)</b> Molecular basis of altered expression of the HMG-CoA reductase gene in genetically hypertensive mice - <b>Nitish Mahapatra (India)</b></p> <p>2 <b>(1040-1050)</b> Increased migration of monocytes associated with enhanced transient receptor: potential canonical Type 3 channels in human essential hypertension - <b>Zhidan Luo (China)</b></p> <p>3 <b>(1050-1100)</b> On CpG island methylation status of mitofusin-2 in vascular smooth muscle cell of phenotype modulation - <b>Zhong Guang-Wei (China)</b></p> <p>4 <b>(1100-1110)</b> Gender-specific association between polymorphisms in WNK3 gene and essential hypertension in a Chinese population - <b>Shengnan Wu (China)</b></p> <p>5 <b>(1110-1120)</b> Association of common variants of CYP4A11 and CYP4F2 with stroke in the Chinese Han Population - <b>Hu Ding (China)</b></p>
<b>1200-1240</b>	<b>LUNCH</b>				
<b>1240-1415</b>	<p><b>SYMPOSIUM 38 (Plenary)</b></p> <p><b>GUIDELINES AND LOCAL RECOMMENDATIONS</b></p>				

**World Hypertension Congress 2009 (Oct 29~Nov 1, 2009)**

	<p><b>Chairpersons: Lisheng Liu (China), Suzanne Oparil (US)</b></p> <p>2 <b>(1240-1250)</b> Brazilian and Latin American guidelines for the treatment of hypertension - <b>Oswaldo Kohlmann (Brazil)</b></p> <p>3 <b>(1250-1300)</b> Korean hypertension guidelines in comparison with the global hypertension guidelines - <b>Cheol-Ho Kim (Korea)</b></p> <p>4 <b>(1300-1310)</b> ESH guidelines – <b>Gianfranco Parati (Italy)</b></p> <p>5 <b>(1310-1320)</b> Progress in hypertension management: implications for new guidelines (JNC 8) - <b>Suzanne Oparil (US)</b></p> <p>6 <b>(1320-1330)</b> Japan guidelines - <b>Kazuaki Shimamoto (Japan)</b></p> <p>7 <b>(1330-1340)</b> African guidelines - <b>Daniel Lemogoum (Cameroon)</b></p> <p>8 <b>(1340-1350)</b> Canadian guidelines - <b>Norm Campbell (Canada)</b></p> <p>9 <b>(1350-1400)</b> China guideline updates - <b>Zhaosu Wu (China)</b></p> <p>10 <b>(1400-1410)</b> 2009 Taiwan Hypertension Guidelines: what is new and what is unique - <b>Tzung-Dau Wang (Taiwan, China)</b></p>				
<p><b>1410-1430</b></p>	<p><b>CLOSING-</b> Arun Chockalingam (Canada)</p>				